Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease (NCT07061938)
Phase 1b/2a Prospective, Open Label, Multicenter, Single Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Immunoglobulin G4-Related Disease
🩺 Plain-English Summary (8th-Grade Level)
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
Who can join: Review the eligibility criteria below.
Location: Emory University — Atlanta, Georgia
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Emory University — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Kanazawa Medical University Hospital — Kahoku-gun, JP
📞 Contact the Study Coordinator
Phone: (415) 366-7822
Email: clinical@acepodiabio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgG4 Related Disease
- A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease — Palo Alto, California
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease — Stanford, California
Explore by condition: All IgG4 Related Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.